2017 February | The Journal of Targeted Therapies in Cancer

Immune Checkpoint Approaches in AML and MDS: A Next Frontier?

March 07, 2017

Clinical Articles

The researchers discuss the rationale for checkpoint-based therapies including antibodies to PD-1/PD-L1 and CTLA-4, an overview of clinical experience with these agents, and future considerations and combinations of these agents.

Immune Checkpoint Inhibitors in CRC

March 02, 2017

Clinical Articles

Ali Maawy, MD, and Patrick M. Boland, MD, provide a brief review of the immune environment of colorectal cancer (CRC) and recently reported studies of immunotherapy in CRC.

Axicabtagene Ciloleucel Demonstrates Safety and Efficacy in Lymphoma

February 10, 2017

Clinical Articles

Results from the phase I portion of the first trial testing axicabtagene ciloleucel, an autologous CD3ζ/CD28-based CAR T-cell therapy, indicate that the regimen can safely be administered and lead to durable CR after more than 12 months in refractory diffuse large B-cell lymphoma.

Missing Tumor-Specific Mutations Lead to Increased Resistance to Checkpoint Inhibitors

February 10, 2017

Clinical Articles

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that acquired resistance to checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.